Diabetes Obes Metab

Do GLP‑1 receptor agonists lower Parkinson’s risk?

March 2, 2026

A large TriNetX cohort study matched 92,485 adults with type 2 diabetes (T2DM) initiating GLP‑1 receptor agonists (RAs) to new metformin users. Overall Parkinson’s disease incidence didn't differ between groups (adjusted hazard ratio [aHR], 0.91; 95% confidence interval, 0.79–1.05). However, between years 5 and 10 of follow‑up, GLP‑1 RA use was associated with lower Parkinson's disease risk (aHR, 0.56; 95% CI, 0.34–0.93). All‑cause mortality was similar, and validation analyses supported internal consistency. Authors propose a possible delayed neuroprotective effect.

Clinical takeaway: When selecting long‑term glucose‑lowering therapy for patients with T2DM, consider that GLP‑1 RAs may offer a potential mid‑term neurologic advantage over metformin.

Source:

Sun M, et al. (2026, January 26). Diabetes Obes Metab. GLP-1RAs versus metformin and Parkinson's risk in type 2 diabetes. https://pubmed.ncbi.nlm.nih.gov/41582696/